ArticleDiscover oncology2025
GTV delineating for patients with postoperative glioma based on enhanced T2-FLAIR sequence instead of enhanced T1-TFE sequence: a feasibility study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate the comparison of MRI Enhanced T2-Fluid Attenuated Inversion Recovery(T2-FLAIR+C) sequence and Enhanced T1-Turbo Field Echo(T1-TFE+C) sequence in delineating Gross Tumor Volume (GTV) of postoperative glioma.
methodTwenty patients with postoperative glioma underwent MRI simulation(MRI-sim) were enrolled. The T1-TFE+C sequence and T2-FLAIR+C sequence were separately registered with CT simulation(CT-sim). GTV was delineated by the same physician based on CT/T1 and CT/T2, respectively. Subsequently, the number, volume and overlapping ratio(OR) of GTV between the two groups were quantified and analyzed statistically. The signal intensity(SI) of the tumor area, normal gray matter and white matter (background of normal brain tissue)were measured on T1-TFE+C and T2-FLAIR+C sequences, respectively. The contrast ratio(CR) of the tumor in the two sequences were calculated and statistically analyzed.
resultsThe volumes of GTV delineated based on CT/T1 and CT/T2 were (55.89 ± 30.20) cm
conclusionThe volume of GTV delineated by T2-FLAIR+C was slightly larger compared to that by T1-TFE+C, and T2-FLAIR+C could provide a more comprehensive range of GTV delineation. CR was statistically significant between the two groups (P < 0.05), and T2-FLAIR+C demonstrated the ability to accurately depict changes in tumor boundaries and surrounding edema with a higher tumor enhancement signal. Therefore, GTV delineation of gliomas based on T2-FLAIR+C may offer certain advantages and could potentially serve as a complete replacement for T1-TFE+C in future clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.